• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Innovus Pharma adds Randy Berholtz as EVP, Corporate Development and General Counsel

Innovus Pharma adds Randy Berholtz as EVP, Corporate Development and General Counsel

January 9, 2017
CenterWatch Staff

Innovus Pharmaceuticals, an emerging commercial stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men’s and women’s health and respiratory diseases, has announced that Randy Berholtz will join the management team as executive vice president, Corporate Development and General Counsel. A life sciences business and legal veteran with decades of experience, Berholtz joins Innovus Pharma to expand its corporate development efforts to find and enter into additional collaborations to expand the breadth and depth of product offerings on a worldwide basis.

“I am very excited to bring on Randy at this important period of commercial growth for Innovus Pharma,” said Dr. Bassam Damaj, Innovus’ chief executive officer. “His business, legal and deal-making expertise and experience will help us to increase our capacity to find, negotiate with and enter into additional acquisitions and partnerships that will help us increase our product offerings and expand our international commercialization efforts to take our company to the next stage.”

“I am very excited to be joining the Innovus Pharma executive team at this important point in the Company’s growth,” said Berholtz. “I look forward to working with Bassam, Robert Hoffman and the entire Innovus Pharma team on growing the company’s product portfolio, expanding its corporate partnerships and increasing its revenues.”

Berholtz will oversee Innovus Pharma’s corporate development, business development and legal areas.

Berholtz was recently the founding partner of the Sorrento Valley Law Group, a healthcare and life sciences law firm and had previously been a part-time consultant for the company from July 2013 to mid-May 2016. Previously, from 2011 to 2013, he was the executive vice president, General Counsel and Secretary of Apricus Biosciences; from 2004 to 2010, he was the vice president, General Counsel and Secretary of the ACON Group of private U.S. and Chinese life science companies; from 2003 to 2004, he was the chief operating officer and General Counsel to Inglewood Ventures, a life sciences venture capital firm; and from 2000 to 2003, he held multiple titles and rose to become the Acting General Counsel and Secretary of Nanogen, a genomics tools company. From 1992 to 2000, Berholtz was in private practice with law firms in New York and San Diego and from 1990 to 1991, he was a law clerk to Judge Jerry E. Smith on the U.S. Court of Appeals for the Fifth Circuit.

Berholtz is a member of the board of directors of Hispanica International Delights of America, an ethnic food company and Larada Health, a private company in the medical supply business and is a Senior Advisor to Mesa Verde Ventures, a life sciences venture capital firm. Berholtz received his B.A. from Cornell University, his M.Litt. from Oxford University where he was a Rhodes Scholar, his J.D. from Yale University and his M.B.A. from the University of San Diego.

Upcoming Events

  • 12Apr

    The Patient Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 27Apr

    Califf’s FDA, 2023 and Beyond: Key Developments, Insights and Analysis

  • 17May

    2023 WCG Avoca Quality Consortium Summit

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Five Ws

    Consider the Five ‘W’s to Understand Potential Participants

  • QandA-360x240.png

    Perspectives from Smaller-Sized CROs: Q&A with Cheryle Evans

  • White House

    Trial Stakeholders Advise White House on Emergency Research Infrastructure

  • SurveywBlueBackground-360x240.png

    Stress Levels Continue to Climb in Healthcare Workforce, Survey Finds

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing